Role of spinal neurotransmitter receptors in itch: New insights into therapies and drug development

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 742-749

  Cevikbas, Ferda ^a   Steinhoff, Martin ^a   Ikoma, Akihiko ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Gastrin releasing peptide; Histamine; Itch; Neurokinin 1 receptor; Opioid; Pruritus; Skin; Spinal cord

Indexed keywords

BRADYKININ RECEPTOR; GABAPENTIN; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; GLUTAMATE RECEPTOR; HISTAMINE; HISTAMINE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MORPHINE; MU OPIATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROKININ 1 RECEPTOR; NEUROTRANSMITTER RECEPTOR; OPIATE; OPIATE RECEPTOR; PREGABALIN; SEROTONIN RECEPTOR; SUBSTANCE P;

CHOLESTASIS; HEMODIALYSIS; HUMAN; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NEUROTRANSMISSION; NONHUMAN; PRESYNAPTIC NERVE; PROTEIN EXPRESSION; PRURITUS; REVIEW; SPINAL CORD; SPINAL CORD DORSAL HORN; UNSPECIFIED SIDE EFFECT;

ANIMALS; DRUG DESIGN; GASTRIN-SECRETING CELLS; HUMANS; NEUROTRANSMITTER AGENTS; PRURITUS; RECEPTORS, BRADYKININ; RECEPTORS, GLUTAMATE; RECEPTORS, HISTAMINE; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID; RECEPTORS, SEROTONIN; SPINAL CORD;

EID: 79960421499     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00201.x     Document Type: Review

References (131)

1. Ikoma A, Steinhoff M, Stander S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006;7:535-547.
2. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006;126:1705-1718.
3. Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain 1988;33:149-160.
4. Mikuni I, Hirai H, Toyama Y, Takahata O, Iwasaki H. Efficacy of intrathecal morphine with epidural ropivacaine infusion for postcesarean analgesia. J Clin Anesth 2010;22:268-273.
5. Rosow CE, Moss J, Philbin DM, Savarese JJ. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982;56:93-96.
6. Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert W. Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: An in vivo microdialysis study in human skin. Anesth Analg 2004;98:364-370 [table].
7. Krause L, Shuster S. Mechanism of action of antipruritic drugs. Br Med J (Clin Res Ed) 1983;287:1199-1200.
8. Girgin NK, Gurbet A, Turker G, Aksu H, Gulhan N. Intrathecal morphine in anesthesia for cesarean delivery: Dose-response relationship for combinations of low-dose intrathecal morphine and spinal bupivacaine. J Clin Anesth 2008;20:180-185.
9. Bromage PR, Camporesi EM, Durant PA, Nielsen CH. Rostral spread of epidural morphine. Anesthesiology 1982;56:431-436.
10. Saiah M, Borgeat A, Wilder-Smith OH, Rifat K, Suter PM. Epidural-morphine-induced pruritus: Propofol versus naloxone. Anesth Analg 1994;78:1110-1113.
11. Ko MC, Song MS, Edwards T, Lee H, Naughton NN. The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther 2004;310:169-176.
12. Thomas DA, Williams GM, Iwata K, Kenshalo DR Jr., Dubner R. The medullary dorsal horn. A site of action of morphine in producing facial scratching in monkeys. Anesthesiology 1993;79:548-554.
13. Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiate and H1 antagonist effects on histamine induced pruritus and alloknesis. Pain 1997;73:239-243.
14. Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996;348:1552-1554.
15. Bergasa NV. The pruritus of cholestasis. J Hepatol 2005;43:1078-1088.
16. Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol 2010;63:680-688.
17. McRae CA, Prince MI, Hudson M, Day CP, James OF, Jones DE. Pain as a complication of use of opiate antagonists for symptom control in cholestasis. Gastroenterology 2003;125:591-596.
18. Ko MC, Naughton NN. An experimental itch model in monkeys: Characterization of intrathecal morphine-induced scratching and antinociception. Anesthesiology 2000;92:795-805.
19. Ko MC, Husbands SM. Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther 2009;328:193-200.
20. Commiskey S, Fan LW, Ho IK, Rockhold RW. Butorphanol: Effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci 2005;98:109-116.
21. Lee H, Naughton NN, Woods JH, Ko MC. Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology 2007;107:478-485.
22. Butelman ER, Ko MC, Traynor JR, Vivian JA, Kreek MJ, Woods JH. GR89, 696: A potent kappa-opioid agonist with subtype selectivity in rhesus monkeys. J Pharmacol Exp Ther 2001;298:1049-1059.
23. Mizoguchi H, Hung KC, Leitermann R, et al. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice. Eur J Pharmacol 2003;461:35-39.
24. Wang Y, Tang K, Inan S, et al. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 2005;312:220-230.
25. Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002;435:259-264.
26. Kamei J, Nagase H. Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol 2001;418:141-145.
27. Ko MC, Lee H, Song MS, et al. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J Pharmacol Exp Ther 2003;305:173-179.
28. Inan S, Dun NJ, Cowan A. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice. Neuroscience 2009;163:23-33.
29. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16:3742-3747.
30. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25:1251-1257.
31. Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007;18:1457-1466.
32. Ischia J, Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide: Different forms, different functions. Biofactors 2009;35:69-75.
33. Hampton LL, Ladenheim EE, Akeson M, et al. Loss of bombesin-induced feeding suppression in gastrin-releasing peptide receptor-deficient mice. Proc Natl Acad Sci U S A 1998;95:3188-3192.
34. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448:700-703.
35. Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. Cellular basis of itch sensation. Science 2009;325:1531-1534.
36. Liu Q, Tang Z, Surdenikova L, et al. Sensory neuron-specific GPCR Mrgprs are itch receptors mediating chloroquine-induced pruritus. Cell 2009;139:1353-1365.
37. Dong X, Han S, Zylka MJ, Simon MI, Anderson DJ. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. Cell 2001;106:619-632.
38. Zylka MJ, Dong X, Southwell AL, Anderson DJ. Atypical expansion in mice of the sensory neuron-specific Mrg G protein-coupled receptor family. Proc Natl Acad Sci U S A 2003;100:10043-10048.
39. Handwerker HO, Schmelz M. Pain: Itch without pain-a labeled line for itch sensation Nat Rev Neurol 2009;5:640-641.
40. Malenka RC, Bear MF. LTP and LTD: An embarrassment of riches. Neuron 2004;44:5-21.
41. Zhuo M. Plasticity of NMDA receptor NR2B subunit in memory and chronic pain. Mol Brain 2009;2:4.
42. Woolf CJ, Salter MW. Neuronal plasticity: Increasing the gain in pain. Science 2000;288:1765-1769.
43. Ikoma A, Rukwied R, Stander S, Steinhoff M, Miyachi Y, Schmelz M. Neuronal sensitization for histamine-induced itch in lesional skin of patients with atopic dermatitis. Arch Dermatol 2003;139:1455-1458.
44. Ikoma A, Fartasch M, Heyer G, Miyachi Y, Handwerker H, Schmelz M. Painful stimuli evoke itch in patients with chronic pruritus: Central sensitization for itch. Neurology 2004;62:212-217.
45. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr Pharm Des 2005;11:2977-2994.
46. Hocking G, Cousins MJ. Ketamine in chronic pain management: An evidence-based review. Anesth Analg 2003;97:1730-1739.
47. Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995;61:215-220.
48. Jinks SL, Carstens E. Spinal NMDA receptor involvement in expansion of dorsal horn neuronal receptive field area produced by intracutaneous histamine. J Neurophysiol 1998;79:1613-1618.
49. Tan-No K, Taira A, Wako K, et al. Intrathecally administered spermine produces the scratching, biting and licking behaviour in mice. Pain 2000;86:55-61.
50. Boyce S, Wyatt A, Webb JK, et al. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: Correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 1999;38:611-623.
51. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-540.
52. Gogas KR. Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 2006;6:68-74.
53. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: An overview of recent guidelines. Am J Med 2009;122:S22-S32.
54. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-5776.
55. Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacol Sci 2006;100:471-486.
56. Scheinfeld N. The role of gabapentin in treating diseases with cutaneous manifestations and pain. Int J Dermatol 2003;42:491-495.
57. Winhoven SM, Coulson IH, Bottomley WW. Brachioradial pruritus: Response to treatment with gabapentin. Br J Dermatol 2004;150:786-787.
58. Yesudian PD, Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005;141:1507-1509.
59. Porzio G, Aielli F, Verna L, et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006;32:397-398.
60. Roosterman D, Goerge T, Schneider SW, Bunnett NW, Steinhoff M. Neuronal control of skin function: The skin as a neuroimmunoendocrine organ. Physiol Rev 2006;86:1309-1379.
61. Andoh T, Nagasawa T, Satoh M, Kuraishi Y. Substance P induction of itch-associated response mediated by cutaneous NK1 tachykinin receptors in mice. J Pharmacol Exp Ther 1998;286:1140-1145.
62. Smith ES, Blass GR, Lewin GR, Park TJ. Absence of histamine-induced itch in the African naked mole-rat and "rescue" by Substance P. Mol Pain 2010;6:29.
63. Andoh T, Katsube N, Maruyama M, Kuraishi Y. Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice. J Invest Dermatol 2001;117:1621-1626.
64. Pincelli C, Fantini F, Massimi P, Girolomoni G, Seidenari S, Giannetti A. Neuropeptides in skin from patients with atopic dermatitis: An immunohistochemical study. Br J Dermatol 1990;122:745-750.
65. Wallengren J, Moller H, Ekman R. Occurrence of substance P, vasoactive intestinal peptide, and calcitonin gene-related peptide in dermographism and cold urticaria. Arch Dermatol Res 1987;279:512-515.
66. Chan J, Smoller BR, Raychauduri SP, Jiang WY, Farber EM. Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997;289:611-616.
67. Hagermark O, Hokfelt T, Pernow B. Flare and itch induced by substance P in human skin. J Invest Dermatol 1978;71:233-235.
68. Weidner C, Klede M, Rukwied R, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysis study. J Invest Dermatol 2000;115:1015-1020.
69. Costa SK, Starr A, Hyslop S, Gilmore D, Brain SD. How important are NK1 receptors for influencing microvascular inflammation and itch in the skin? Studies using Phoneutria nigriventer venom. Vascul Pharmacol 2006;45:209-214.
70. Bleazard L, Hill RG, Morris R. The correlation between the distribution of the NK1 receptor and the actions of tachykinin agonists in the dorsal horn of the rat indicates that substance P does not have a functional role on substantia gelatinosa (lamina II) neurons. J Neurosci 1994;14:7655-7664.
71. Liu H, Brown JL, Jasmin L, et al. Synaptic relationship between substance P and the substance P receptor: Light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. Proc Natl Acad Sci U S A 1994;91:1009-1013.
72. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 1994;347:249-274.
73. Brown JL, Liu H, Maggio JE, Vigna SR, Mantyh PW, Basbaum AI. Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol 1995;356:327-344.
74. Littlewood NK, Todd AJ, Spike RC, Watt C, Shehab SA. The types of neuron in spinal dorsal horn which possess neurokinin-1 receptors. Neuroscience 1995;66:597-608.
75. Spike RC, Puskar Z, Andrew D, Todd AJ. A quantitative and morphological study of projection neurons in lamina I of the rat lumbar spinal cord. Eur J Neurosci 2003;18:2433-2448.
76. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-158.
77. Vergnolle N, Bunnett NW, Sharkey KA, et al. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nat Med 2001;7:821-826.
78. Mantyh PW, Rogers SD, Honore P, et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 1997;278:275-279.
79. Nichols ML, Allen BJ, Rogers SD, et al. Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 1999;286:1558-1561.
80. Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 2000;67:419-426.
81. Goldstein DJ, Offen WW, Klein EG, et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001;21:102-106.
82. Goldstein DJ, Wang O, Gitter BD, Iyengar S. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 2001;24:16-22.
83. Duval A, Dubertret L. Aprepitant as an antipruritic agent N Engl J Med 2009;361:1415-1416.
84. Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: A novel antipruritic strategy. PLoS One 2010;5:e10968.
85. Calixto JB, Cabrini DA, Ferreira J, Campos MM. Kinins in pain and inflammation. Pain 2000;87:1-5.
86. Couture R, Harrisson M, Vianna RM, Cloutier F. Kinin receptors in pain and inflammation. Eur J Pharmacol 2001;429:161-176.
87. Chapman V, Dickenson AH. The spinal and peripheral roles of bradykinin and prostaglandins in nociceptive processing in the rat. Eur J Pharmacol 1992;219:427-433.
88. Ferreira J, Campos MM, Araujo R, Bader M, Pesquero JB, Calixto JB. The use of kinin B1 and B2 receptor knockout mice and selective antagonists to characterize the nociceptive responses caused by kinins at the spinal level. Neuropharmacology 2002;43:1188-1197.
89. Wang H, Kohno T, Amaya F, et al. Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic transmission. J Neurosci 2005;25:7986-7992.
90. Hosogi M, Schmelz M, Miyachi Y, Ikoma A. Bradykinin is a potent pruritogen in atopic dermatitis: A switch from pain to itch. Pain 2006;126:16-23.
91. Hayashi I, Majima M. Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists. Br J Pharmacol 1999;126:197-204.
92. Costa R, Marotta DM, Manjavachi MN, et al. Evidence for the role of neurogenic inflammation components in trypsin-elicited scratching behaviour in mice. Br J Pharmacol 2008;154:1094-1103.
93. Ui H, Andoh T, Lee JB, Nojima H, Kuraishi Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006;530:172-178.
94. Shimada SG, Shimada KA, Collins JG. Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. Eur J Pharmacol 2006;530:281-283.
95. Nakano T, Andoh T, Lee JB, Kuraishi Y. Different dorsal horn neurons responding to histamine and allergic itch stimuli. Neuroreport 2008;19:723-726.
96. Akiyama T, Carstens MI, Carstens E. Excitation of mouse superficial dorsal horn neurons by histamine and/or PAR-2 agonist: Potential role in itch. J Neurophysiol 2009;102:2176-2183.
97. Costa R, Manjavachi MN, Motta EM, et al. The role of kinin B1 and B2 receptors in the scratching behaviour induced by proteinase-activated receptor-2 agonists in mice. Br J Pharmacol 2010;159:888-897.
98. Hagermark O. Peripheral and central mediators of itch. Skin Pharmacol 1992;5:1-8.
99. Nojima H, Carstens E. 5-Hydroxytryptamine (5-HT)2 receptor involvement in acute 5-HT-evoked scratching but not in allergic pruritus induced by dinitrofluorobenzene in rats. J Pharmacol Exp Ther 2003;306:245-252.
100. Yamaguchi T, Nagasawa T, Satoh M, Kuraishi Y. Itch-associated response induced by intradermal serotonin through 5-HT2 receptors in mice. Neurosci Res 1999;35:77-83.
101. Jinks SL, Carstens E. Responses of superficial dorsal horn neurons to intradermal serotonin and other irritants: Comparison with scratching behavior. J Neurophysiol 2002;87:1280-1289.
102. Akiyama T, Merrill AW, Carstens MI, Carstens E. Activation of superficial dorsal horn neurons in the mouse by a PAR-2 agonist and 5-HT: Potential role in itch. J Neurosci 2009;29:6691-6699.
103. Fan P. Nonopioid mechanism of morphine modulation of the activation of 5-hydroxytryptamine type 3 receptors. Mol Pharmacol 1995;47:491-495.
104. George RB, Allen TK, Habib AS. Serotonin receptor antagonists for the prevention and treatment of pruritus, nausea, and vomiting in women undergoing cesarean delivery with intrathecal morphine: A systematic review and meta-analysis. Anesth Analg 2009;109:174-182.
105. Bonnet MP, Marret E, Josserand J, Mercier FJ. Effect of prophylactic 5-HT3 receptor antagonists on pruritus induced by neuraxial opioids: A quantitative systematic review. Br J Anaesth 2008;101:311-319.
106. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: Effectiveness of ondansetron. Pain 1995;61:33-37.
107. Balaskas EV, Bamihas GI, Karamouzis M, Voyiatzis G, Tourkantonis A. Histamine and serotonin in uremic pruritus: Effect of ondansetron in CAPD-pruritic patients. Nephron 1998;78:395-402.
108. Dogrul A, Seyrek M. Systemic morphine produce antinociception mediated by spinal 5-HT7, but not 5-HT1A and 5-HT2 receptors in the spinal cord. Br J Pharmacol 2006;149:498-505.
109. Yanarates O, Dogrul A, Yildirim V, et al. Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways. Anesthesiology 2010;112:696-710.
110. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. J Neurosci 1997;17:8003-8008.
111. Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch. Nat Neurosci 2001;4:72-77.
112. Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 2009;39:1786-1800.
113. Greaves MW, Davies MG. Histamine receptors in human skin: Indirect evidence. Br J Dermatol 1982;107(Suppl 23):101-105.
114. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 2010;130:1023-1033.
115. Rossbach K, Wendorff S, Sander K, et al. Histamine H4 receptor antagonism reduces hapten-induced scratching behaviour but not inflammation. Exp Dermatol 2009;18:57-63.
116. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: The search for new antihistamines. Nat Rev Drug Discov 2008;7:41-53.
117. Yamaura K, Oda M, Suwa E, Suzuki M, Sato H, Ueno K. Expression of histamine H4 receptor in human epidermal tissues and attenuation of experimental pruritus using H4 receptor antagonist. J Toxicol Sci 2009;34:427-431.
118. Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL. Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 2007;119:176-183.
119. Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004;142:374-380.
120. Hossen MA, Sugimoto Y, Kayasuga R, Kamei C. Involvement of histamine H3 receptors in scratching behaviour in mast cell-deficient mice. Br J Dermatol 2003;149:17-22.
121. Hossen MA, Inoue T, Shinmei Y, Fujii Y, Watanabe T, Kamei C. Role of substance P on histamine H(3) antagonist-induced scratching behavior in mice. J Pharmacol Sci 2006;100:297-302.
122. Hill SJ, Emson PC, Young JM. The binding of [3H]mepyramine to histamine H1 receptors in guinea-pig brain. J Neurochem 1978;31:997-1004.
123. Ninkovic M, Hunt SP, Gleave JR. Localization of opiate and histamine H1-receptors in the primate sensory ganglia and spinal cord. Brain Res 1982;241:197-206.
124. Taylor JE, Yaksh TL, Richelson E. Histamine H1 receptors in the brain and spinal cord of the cat. Brain Res 1982;243:391-394.
125. Sakurada S, Watanabe H, Mizoguchi H, et al. Involvement of the histaminergic system in the nociceptin-induced pain-related behaviors in the mouse spinal cord. Pain 2004;112:171-182.
126. Watanabe C, Orito T, Watanabe H, et al. Intrathecal high-dose histamine induces spinally-mediated nociceptive behavioral responses through a polyamine site of NMDA receptors. Eur J Pharmacol 2008;581:54-63.
127. Yoshida A, Mobarakeh JI, Sakurai E, et al. Intrathecally-administered histamine facilitates nociception through tachykinin NK1 and histamine H1 receptors: A study in histidine decarboxylase gene knockout mice. Eur J Pharmacol 2005;522:55-62.
128. Mobarakeh JI, Sakurada S, Hayashi T, et al. Enhanced antinociception by intrathecally-administered morphine in histamine H1 receptor gene knockout mice. Neuropharmacology 2002;42:1079-1088.
129. Mobarakeh JI, Takahashi K, Sakurada S, Kuramasu A, Yanai K. Enhanced antinociceptive effects of morphine in histamine H2 receptor gene knockout mice. Neuropharmacology 2006;51:612-622.
130. Mobarakeh JI, Takahashi K, Yanai K. Enhanced morphine-induced antinociception in histamine H3 receptor gene knockout mice. Neuropharmacology 2009;57:409-414.
131. Strakhova MI, Nikkel AL, Manelli AM, et al. Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res 2009;1250:41-48.